Tolbutamide

Type 2 Diabetes
Treatment
2 FDA approvals
20 Active Studies for Tolbutamide

What is Tolbutamide

TolbutamideThe Generic name of this drug
Treatment SummaryTolbutamide is a pill used to treat non-insulin-dependent diabetes. It belongs to a class of drugs called sulfonylureas, which work by stimulating the pancreas to release more insulin. This increases the amount of glucose taken up by cells in the body and decreases the amount of glucose made by the liver. Sulfonylureas can cause weight gain, and may cause low blood sugar levels (hypoglycemia), especially in elderly, debilitated, and malnourished individuals. The drug is metabolized in the liver and then excreted in the urine and feces.
Tolbutamideis the brand name
image of different drug pills on a surface
Tolbutamide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tolbutamide
Tolbutamide
1979
2

Approved as Treatment by the FDA

Tolbutamide, also called Tolbutamide, is approved by the FDA for 2 uses which include Type 2 Diabetes and Type 2 Diabetes Mellitus .
Type 2 Diabetes
Helps manage Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Helps manage Type 2 Diabetes Mellitus

Effectiveness

How Tolbutamide Affects PatientsTolbutamide is a diabetes medicine used in combination with a healthy diet to help lower blood sugar levels in people with type 2 diabetes. It is more powerful than the related second-generation drug glipizide. Tolbutamide works by helping the pancreas release more insulin and helping the body use the insulin better. In order for this drug to be effective, the pancreas must be able to produce insulin.
How Tolbutamide works in the bodySulfonylureas lower blood sugar in people with type 2 diabetes by encouraging the pancreas to release insulin. They do this by attaching to a receptor on the beta cells of the pancreas and blocking certain potassium channels. This causes an influx of calcium and other molecules, leading to the release of insulin-containing granules out of the cell, similar to the effect of glucose.

When to interrupt dosage

The recommended dosage of Tolbutamide is dependent upon the recognized condition. The quantity of dosage fluctuates, in accordance with the administration technique featured in the table beneath.
Condition
Dosage
Administration
Type 2 Diabetes
500.0 mg, , 1000.0 mg
, Oral, Tablet, Tablet - Oral

Warnings

Tolbutamide Contraindications
Condition
Risk Level
Notes
Diabetic Ketoacidosis
Do Not Combine
Diabetes Mellitus, Type 1
Do Not Combine
There are 20 known major drug interactions with Tolbutamide.
Common Tolbutamide Drug Interactions
Drug Name
Risk Level
Description
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Tolbutamide.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Tolbutamide.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Tolbutamide.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Tolbutamide.
Erlotinib
Major
The metabolism of Erlotinib can be decreased when combined with Tolbutamide.
Tolbutamide Toxicity & Overdose RiskThe lowest toxic dose of the drug in mice has been found to be 2600mg/kg.
image of a doctor in a lab doing drug, clinical research

Tolbutamide Novel Uses: Which Conditions Have a Clinical Trial Featuring Tolbutamide?

162 active clinical trials are in progress to explore the potential of Tolbutamide in treating Type 2 Diabetes.
Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
172 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Tolbutamide Reviews: What are patients saying about Tolbutamide?

1Patient Review
6/12/2014
Tolbutamide for Type 2 Diabetes Mellitus
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about tolbutamide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the mechanism of action of tolbutamide?

"Tolbutamide works by stimulating the pancreas to secrete insulin, and by helping the body to use insulin efficiently. The pancreas must be able to produce insulin for this drug to be effective."

Answered by AI

What is the generic name of tolbutamide?

"Orinase (tolbutamide) is a medication used to treat type 2 diabetes. The recommended dose is 500 mg two or three times daily. Possible side effects include low blood sugar, nausea, and headache."

Answered by AI

What is tolbutamide used for?

"Tolbutamide is used to treat high blood sugar levels caused by type 2 diabetes mellitus. In type 2 diabetes, your body does not work properly to store excess sugar and the sugar remains in your bloodstream."

Answered by AI

What are the side effects of tolbutamide?

"The following are symptoms of the disease: nausea, feeling full in the upper abdomen, heartburn, rash, headache, and changes in taste."

Answered by AI

Clinical Trials for Tolbutamide

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Tolbutamide clinical trials? We made a collection of clinical trials featuring Tolbutamide, we think they might fit your search criteria.Go to Trials
Have you considered Tolbutamide clinical trials? We made a collection of clinical trials featuring Tolbutamide, we think they might fit your search criteria.Go to Trials
Image of Jefferson Health New Jersey in Sewell, United States.

Continuous vs Finger-stick Glucose Monitoring for Type 2 Diabetes in Pregnancy

18+
Female
Sewell, NJ
The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements. Patients involved in the study will be assigned to either: 1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM) Patients will be randomize in a 1:1 ratio. FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery. CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days. Percent adherence will be recorded from the time you were randomized to a study group until delivery.
Recruiting
Has No Placebo
Jefferson Health New Jersey (+1 Sites)
Image of McMaster University in Hamilton, Canada.

Health Coaching for Type 2 Diabetes and Mental Health

18+
All Sexes
Hamilton, Canada
Managing both type 2 diabetes and mental health challenges can be difficult, and many people do not receive care that supports both. This study looks at how virtual health coaching and support from interdisciplinary care teams can help people better manage their health. The purpose of this study is to test the effectiveness of a virtual health coaching program for adults living with type 2 diabetes and mental health challenges compared to usual care. The Technology-Enabled Collaborative Care for type 2 Diabetes and Mental health (TECC-DM) program includes weekly coaching calls, support from an interdisciplinary care team, and online tools to aid self-management. The findings from this study will be used to help improve services for people who have type 2 diabetes and co-occurring mental health symptoms.
Waitlist Available
Has No Placebo
McMaster UniversityCarly Whitmore, RN PhD
Have you considered Tolbutamide clinical trials? We made a collection of clinical trials featuring Tolbutamide, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security